Sanofi
English

Recruiting

NCT07118306

COPD (Chronic Obstructive Pulmonary Disease)

COPD Exacerbation Follow Up

+ 40 year(s)

Study targets participants aged 40 year(s) and older

All gender

This study targets all gender participants

N/A

general.n_aDetailText

485 participants

Study involves a large group of participants

2 locations

Available in numerous locations

Study Overview

The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.

Study Details

Time perspective: This study will collect data prospectively for the Experimental cohort and retrospectively for the Control cohort. There is also an Exploratory cohort which will collect retrospective and prospective data.

Eligibility Criteria

Inclusion Criteria:

  • Patients aged 40 years or older at the time of arrival to the emergency department.
  • Patients with a clinical diagnosis of COPD who present to the emergency department for a moderate or severe COPD exacerbation.
  • A moderate exacerbation is defined as an acute exacerbation requiring either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics.
  • A severe exacerbation is defined as an acute exacerbation requiring hospitalization, or observation for >24 hours in emergency department/urgent care facility or resulting in death.
  • Patients on dual (LABA/LAMA, LABA/ICS, LAMA/ICS) or triple (LABA/LAMA/ICS) long-acting bronchodilator inhalers.

Exclusion Criteria:

  • Patients on bronchodilator inhaler monotherapy.
  • Patients leaving against medical advice or expiring during hospitalization.
  • Patients with tracheostomy.
  • Patients with advanced cancer.
  • Patients who have received a lung transplant.
  • Discharge to hospice care.
  • Transfer to another hospital.
Updated on April 2026. Study ID: NCT07118306